Trial NCT04434144
Publication Chowdhury ATMM, EJMO (2021) (published paper)
Dates: 2020-05-02 to 2020-06-05
Funding: No specific funding (Not applicable)
Conflict of interest: No
Methods | |
RCT | |
Location :
Single center / Bangladesh Follow-up duration (days): 35 | |
Inclusion criteria |
|
Exclusion criteria |
|
Interventions | |
Treatment
IVM+DX Ivermectin: 200 mcg/kg orally once off. Doxycycline: 100 mg orally once a day for 10 days. |
|
Control
HCQ+AZM Hydroxychloroquine: 400 mg once a day orally on the first day, followed by 200 mg twice a day orally for 9 days. Azithromycin: 500 mg orally once a day for 5 days. | |
Participants | |
Randomized participants : IVM+DX=63 HCQ+AZM=62 | |
Characteristics of participants N= 125 Mean age : NR 90 males Severity : Mild: n= 91/ Asymptomatic: n=25 Number of vaccinated participants: NR | |
Primary outcome | |
In the register Number of participants with | |
In the report Negative PCR and resolution of symptoms | |
Documents available |
Protocol NR Statistical plan NR Data-sharing willing stated in the publication: Yes |
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
High |
General comment |
In addition to the published/pre-print article, the trial registry was also used in data extraction and risk of bias assessment. The trial was registered as an observational study and retrospectively after enrollment was already completed. Outcomes not registered were reported in the article. There is no change from the trial registration in the intervention and control treatments.
The study was updated on March 26th, 2021 with data from published report. |